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Abstract
In November 2004, 116 individuals in an elderly nursing home in El Grao de Castello´n, Spain were symptomatically infected
with genogroup II.4 (GII.4) norovirus. The global attack rate was 54.2%. Genotyping of 34 symptomatic individuals regarding
the FUT2 gene revealed that one patient was, surprisingly, a non-secretor, hence indicating secretor-independent infection.
Lewis genotyping revealed that Lewis-positive and negative individuals were susceptible to symptomatic norovirus
infection indicating that Lewis status did not predict susceptibility. Saliva based ELISA assays were used to determine
binding of the outbreak virus to saliva samples. Saliva from a secretor-negative individual bound the authentic outbreak
GII.4 Valencia/2004/Es virus, but did not in contrast to secretor-positive saliva bind VLP of other strains including the GII.4
Dijon strain. Amino acid comparison of antigenic A and B sites located on the external loops of the P2 domain revealed
distinct differences between the Valencia/2004/Es and Dijon strains. All three aa in each antigenic site as well as 10/11
recently identified evolutionary hot spots, were unique in the Valencia/2004/Es strain compared to the Dijon strain. To the
best of our knowledge, this is the first example of symptomatic GII.4 norovirus infection of a Lea+b2 individual homozygous
for the G428A nonsense mutation in FUT2. Taken together, our study provides new insights into the host genetic
susceptibility to norovirus infections and evolution of the globally dominating GII.4 viruses.
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Introduction
Noroviruses (NoV) have emerged as an important cause of
gastroenteritis outbreaks in institutions such as elderly nursing
homes, hotels, hospitals and schools [1,2]. NoV contains a linear
positive-sense single stranded RNA genome of ,7.7 kb in length,
surrounded by a 530 amino acid (aa) long capsid protein (Norwalk
strain), which is folded into two major domains; the conserved S
(shell) domain and a more variable P (protruding) domain [3].
Recent studies have suggested that the protruding NoV capsid
domain, subdivided into P1-1, P1-2 and P2, bear antigenic
determinants affecting the immunological response and host
specificity [4–8].
Transmission of NoV occurs predominantly through contam-
inated food, water, fomites, and by person-to-person through the
fecal-oral route [9]. Evidence of protective immunity to NoV is
controversial; short-term to no immunity has been reported [10–
12] and antibodies do not seem to provide protection, at least not
against the genogroup I Norwalk virus [13]. Furthermore,
volunteer studies have shown that a subset of individuals remain
uninfected even after repeated challenges [10,12,14]. This
information, together with the fact that only low infectious doses
are required for infection, and that attack rates seldom exceeds
70% [15], suggest that some type of inherited factors act to prevent
certain individuals from symptomatic NoV infection. Recent
studies have shown that secretor status; the ability to express histo-
blood group antigen (HBGA) on mucosa and in secretions may
affect the risk of being symptomatically infected by NoV [16–22].
Non-secretors (sese), who do not express the Fuc-TII a1,2-
fucosyltransferase and consequently do not express H type 1 or
Lewis b (Leb) antigens, have been shown to be less susceptible or
even resistant to authentic NoV infections [16,19,21,22]. Approx-
imately 20% of Northern Europeans and Caucasian Americans
are secretor-negative [23]. Furthermore, sero-epidemiology studies
have shown that secretors have significantly higher antibody titers
and prevalence against NoV than non-secretors [24]. However,
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the fact that certain non-secretors are NoV antibody-positive,
suggests that secretor-independent infections do occur [25,26],
maybe with distinct virus strains.
Several mutations are known in the FUT2 gene [23], and some
of them show high ethnic specificity [27,28]. The G428A nonsense
mutation is typically found in the Caucasian population [23,27]
whereas the nonsense C571T mutation is found mainly in Pacific
Islanders [29]. Both these mutations give rise to an early stop
codon, giving a truncated non-functional protein. Homozygous
carriers of any nonsense mutation in the FUT2 gene are called
non-secretors. Homozygous carriers of a missense mutation at
position 385 (A.T) are so called ‘‘weak secretors’’, expressing
lower levels of ABH antigen in saliva and, if Lewis positive, a Lewis
(a+b+) phenotype on erythrocytes [30].
In vitro binding studies have suggested that not only secretor
status but also Lewis status may affect susceptibility to NoV
[31,32]. However, different strains show different binding
patterns, with the worldwide dominating genogroup II.4 strains
expressing the broadest histo-blood group-binding pattern and
thought to be able to infect secretor-positive individuals of all ABO
blood group types irrespective of Le status [31].
Previously, only secretor-positive individuals have been symp-
tomatically infected with the globally dominating GII.4 virus
[16,19,21]. However, Lindesmith and co-workers have shown that
a GII.4 strain detected in 2002 (2002a), bound not only secretor-
positive but also to secretor-negative saliva under certain
conditions [33], hence indicating infection with GII.4 virus also
in non-secretors. In this study we report for the first time of
symptomatic GII.4 NoV infection of an individual homozygous for
the G428A nonsense mutation, a mutation that previously has
been shown to provide complete protection from authentic GII.4
NoV disease [19,21]. Furthermore, we show that antigenic regions
A and B in the P2 domain as well as 10/11 recently identified
evolutionary hot spots proposed to be associated with molecular
evolution [34] are distinct in the outbreak virus.
Results
Description of the outbreak
During November 6th to November 20th 2004 an outbreak of
acute gastroenteritis consisting of 116 cases occurred in an elderly
nursing home in El Grao de Castello´n, Spain. The facility consists
of a building exclusively dedicated to this purpose and includes 65
double-rooms in two floors occupied by 130 residents. In addition,
30 old persons visited the residence daily, which serves as a day-
care center. The nursing home employs 90 healthcare workers and
other staff members, 58 of whom were interviewed.
Out of the 130 residents in the facility, 75 (57.7%) persons suffered
acute gastroenteritis. Sixteen (61.5%) of 26 out-patients were
interviewed and 25 (43.1%) of the staff members experienced an
episode of acute gastroenteritis, with a total of 116 persons affected.
The first three cases were reported on the 6th of November 2004
and since then other residents developed symptoms of acute
gastroenteritis with progression towards the peak of the outbreak
on November 12th 2004, with 44 cases on that date. The global
attack rate was 54.2%. The most common symptoms were
diarrhea (79%) and vomiting (66%), with fever (.37.5uC)
recorded in 13% of the patients. The average duration of
symptoms was less than two days. Five patients were hospitalized,
but no casualties were observed.
The outbreak was caused by a GII.4 strain
NoV were detected by RT-PCR in 27 out of 33 (81.8%) fecal
samples tested from symptomatic patients, both residents and
healthcare workers. As no other enteric virus (rotavirus and enteric
adenovirus) or bacteria were detected from the patients it was
concluded that NoV was the etiological agent of this outbreak.
Sequencing of a portion of the RNA polymerase gene as well as
the P2 region of the capsid gene, from four and three different
specimens respectively, confirmed that the outbreak was caused by
GII.4a-2004 variant virus (Figure 1A and 1B).
The G428A nonsense mutation in FUT2 provides strong
but not absolute protection against symptomatic GII.4
NoV infection
To investigate any association between mutation in the FUT2
gene and resistance to symptomatic infection, genotyping was
performed to identify individuals as secretor-negative, heterozy-
gous secretors or homozygous secretors (Table 1). None of the
individuals were carriers of the mutations at nt 385 (weak secretor)
or at nt 571 in the FUT2 gene. Of the symptomatic individuals
38.2% (13/34) were homozygous secretors and 58.8% (20/34)
were heterozygous secretors. Most interesting was that one (2.9%)
symptomatic female patient (patient A) was found to be
homozygous carrier of the G428A mutation and hence a non-
secretor. Among the asymptomatic/non-exposed individuals,
15.4% (4/26) were homozygous secretors, 23.1% (6/26) were
heterozygous and 61.5% (16/26) were non-secretors. Thus
significant difference (P,0.001) in susceptibility to symptomatic
NoV infection was found between secretors and non-secretors.
Lewis status was not identified as a susceptibility marker
for symptomatic NoV GII.4 infection
While Lea2b+ but not Lea+b2 individuals are highly susceptible
for symptomatic NoV infections, little information is available
regarding Lea2b2 individuals in authentic NoV outbreaks. To
determine whether Lewis status affected the susceptibility of
infection, FUT3 genotyping was performed using PCR with
sequence specific primers (PCR-SSP) [35]. Forty four of 60
individuals (73.3%) were genotyped and the results showed that six
individuals were Lewis-negative due to being homozygous carriers
of inactivating mutations at nt 202 and 314 (two individuals), at nt
59 and 1067 (one individual) and the remaining three being
compound heterozygous at nt 202, 314, 59, 508 or 1067. Two
Lea2b2 individuals were secretor-positive and four were non-
secretors (Table 1). The two secretor-positive Lewis-negative
individuals were both symptomatically infected, whereas none of
the four Lewis-negative non-secretors became ill.
Saliva from secretors and a non-secretor as well as Lewis-
positive and Lewis- negative individuals bound the
outbreak virus strain
Several previous studies have shown that saliva of secretor-
positive but not of secretor-negative individuals can bind NoV
VLP [17] and authentic virus [19]. To investigate the property of
our outbreak virus, the virus was incubated with saliva from
symptomatic and asymptomatic/non-exposed individuals in an
ELISA assay. Figure 2 shows that saliva from secretors bound the
outbreak virus, but interestingly also saliva from one asymptomatic
non-secretor (Lea+b2), referred to as patient B. Because of the
restricted amount of saliva (at the time for first sample collection),
patient A (symptomatically infected non-secretor, Lea+b2) could
not be tested. Figure 2 shows that except for the binding of patient
B, saliva of Lea2b+ but not of Lea+b2 individuals bound the virus
(P,0.001) but more interestingly that Lewis status (positive vs
negative) could not predict binding. The virus bound to saliva
from two of six Lea2b2 individuals both of which were secretors.
Novel GII.4 Disease Pattern
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Figure 1. Phylogenetic analysis of the outbreak Valencia/2004/Es strain. A) Phylogenetic tree of the NoV RNA polymerase gene (region A in
ORF1) from the outbreak (Valencia/2004/Es) and reference strains, obtained from the European Food-borne viruses database [2]. The phylogenetic
tree was constructed using the UPGMA clustering method with distance calculation using the Jukes-Cantor correction for evolutionary rate by
Molecular Evolutionaty Genetics Analysis (MEGA version 2.1). B) Phylogenetic tree of the outbreak (Valencia/2004/Es) capsid P2 domain (aa 279 to
405) and selected reference strains. The phylogenetic tree was constructed using the UPGMA clustering method with distance calculation using the
Poisson correction for evolutionary rate by Molecular Evolutionaty Genetics Analysis (MEGA version 4.1).
doi:10.1371/journal.pone.0005593.g001
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The four Lea2b2 individuals whose saliva could not bind the virus
were all non-secretors.
To confirm the histo-blood group phenotype of the saliva
samples from the two non-secretors, ABO and Lewis phenenotyp-
ing was performed on these saliva samples. Consistent with the
FUT3 Lewis-positive genotyping, the two saliva samples from the
secretor-negative individuals (patient A and B) were identified as
Lea+b2 by phenotyping (Figure 3A). Furthermore, neither patient
A nor B expressed A or B antigen in saliva, which is, indirectly,
further support that they indeed were non-secretors.
To determine if saliva (collected at a second time point) of
patient A (symptomatically infected non-secretor) and patient B
(asymptomatic non-secretor whose saliva bound the outbreak
virus) would bind NoV from different genogroups and genotypes,
a saliva VLP assay was established. Figure 3B shows that saliva
from patients A and B, in contrast to secretor-positive controls
Figure 2. Binding of authentic Valencia/2004/Es virus to saliva. Binding of saliva from secretors and non-secretors to the GII.4 outbreak virus.
Dotted line represents cut-off value. Cut-off value (0.380) was three times the mean OD450 of three known negative control samples. The box shows
interquartile range; the range between the first and third quartiles. Median is marked as a horizontal line within the box. Whiskers represent samples
not more than 1.5 times the box width away from the box. The ring represents a sample within 1.5–3 box lengths from upper or lower edge of the
box and the asterisk marks an extreme case (a value more than 3 box (lenghts from the edge of the box), here representing patient B (asymptomatic
non-secretor).
doi:10.1371/journal.pone.0005593.g002
Table 1. Strong but not absolute correlation between the G428A FUT2 nonsense mutation and symptomatic NoV infection.
No (%) of
patients SeSe Sese sese
LeLe/Lele
sese (Lea+b2)
LeLe/Lele SeSe/
Sese (Lea2b+)
lele SeSe/Sese/
sese (Lea2b2)
Symptomatic 34 (56.7) 13* (38.2) 20* (58.8) 1* (2.9) 1# (3.8) 23# (88.5) 2 (7.7)
Asymptomatic/Nonexposed 26 (43.3) 4* (15.4) 6* (23.1) 16* (61.5) 9# (50) 5# (27.8) 4 (22.2)
Total 60 17 (28.3) 26 (43.3) 17 (28.3) 10 (22.7) 28 (63.6) 6 (13.6)
*SeSe and Sese428 vs. se428se428 P,0.001.
#Lea+b2 vs. Lea2b+ P,0.001.
The Lewis-genotype could be determined in 44 of 60 individuals.
SeSe and LeLe: homozygous wildtype for FUT2 and FUT3.
Sese and Lele: heterozygous for the inactivating mutations of FUT2 and FUT3.
sese and lele: homozygous for the inactivating mutations of FUT2 and FUT3.
Lea+b2: Secretor-negative Lewis-positive phenotype.
Lea2b+: Secretor-positive Lewis-positive phenotype.
Lea2b2: Lewis-negative phenotype.
doi:10.1371/journal.pone.0005593.t001
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(ABLeSe and ALeSe individuals) did not bind VLP from GI.I
(Norwalk strain), GII.3 (Chron1 strain) or GII.4 (Dijon strain), the
latter belonging to the same genotype as the outbreak strain.
Figure 3B also shows that saliva of secretor-negative controls
(ALese and Olese individuals) did not bind any of the VLPs.
The outbreak Valencia strain have distinct amino acids in
antigenic A and B regions of the P2 domain compared to
the Dijon strain
The fact that saliva from a non-secretor (patient B) recognized
the outbreak virus strain and one non-secretor become ill (patient
A) raised the question if the virus had an unique aa sequence in the
P2 domain of the capsid protein. To address this question the P2
domain (nt 667 to nt 1382) of three random samples (no 207, 208,
225) was sequenced and a BLAST search on the NCBI server was
performed. This revealed not only that the Valencian isolates were
identical in the P2 domain but also that the outbreak strain was
most similar to the GII.4 strain Monastir/2003/Tun [EU916960]
isolated in Tunisia 2003 [36]. The Valencia/2004/Es and the
Monastir/2003/Tun strains were identical in every position (aa
248 to 420) except for a conserved substitution at residue 356,
where a valine in the Monastir strain was changed for an
isoleucine in the Valencia strain.
Despite that saliva from patient B bound the outbreak virus, it
did not bind the Dijon VLP used in the binding assay, even though
both strains belong to GII.4. This observation suggested that the
Valencia strain might have HBGA-receptor specific domains
different from the Dijon strain. To investigate this, the aa of the P2
domain of Valencia and Dijon were aligned and compared
(Figure 4). Particular interest was given to antigenic region A and
B of the P2 domain that previously have been associated with
molecular evolution [34]. As illustrated in Figure 4 antigenic
region A and B of the Valencia strain are distinct from the Dijon
strain, all 3 aa in each antigenic site are different. The Valencia
strain have a TQN and a STT motif in the A and B site
respectively, while the Dijon strain have a SHD motif in site A and
a –NN motif in site B. Besides the A and B sites, 11 additional
substitutions (marked number 1–11, Figure 4) were found when
comparing the capsid P2 domain of Valencia and Dijon, 10
(number 2 to 11, figure 4) out of these 11 correlated with
evolutional hot spots identified by Allen and coworkers [34].
Discussion
In this study we describe an outbreak with a GII.4 NoV
affecting both secretors and a non-secretor, but with significantly
higher susceptibility among secretors (76.7%, 33/43) compared to
non-secretors (5.9%, 1/17) (P,0.001). One female non-secretor
(patient A) was symptomatically infected and virus was found in
her stool. FUT2 genotyping identified 38.2% (13/34) of the
infected individuals as homozygous wild types, 58.8% (20/34)
were heterozygous secretors and one (2.9%) was a non-secretor.
Among asymptomatic/non-exposed individuals, 15.4% (4/26)
were homozygous secretors, 23.1% (6/26) were heterozygous
and 61.5% (16/26) were non-secretors. The total frequency of
Figure 3. Detection of histo-blood group antigens and VLP binding to saliva from patient A and B. A) ABO and Lewis histo-blood group
phenotyping of saliva samples from the non-secretor patients A and B confirms a Lea+b2 phenotype. Saliva samples were coated in microtiter wells
and incubated with aA (anti A), aB, aLea or aLeb antibodies separately. The limit of detection for each antibody has been subtracted from each bar.
Both patients reacted strongly only with the aLea antibody and not with the aLeb, aA or aB antibodies and were thereby classified as Lea+b2. A, AB or
O denotes blood groups, Le or le denotes Lewis positive or Lewis negative, respectively, and Se or se denotes secretors or non-secretors. B) Saliva
from non-secretor patients A and B or non-secretor controls do not bind Chron, Dijon or Norwalk VLPs whereas saliva from secretors bind all three
strains.
doi:10.1371/journal.pone.0005593.g003
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non-secretors was 28.3% (17/60) and was thus higher than the
frequency of the Northern European population, which is
approximately 20% [19,21,23,37]. Saliva from a non-infected
non-secretor (patient B) recognized the outbreak virus in a saliva-
based ELISA, suggesting that the virus may have different binding
properties from what is generally observed among GII.4 NoV
strains. A similar finding has previously been reported by
Lindesmith and co-workers [33] who demonstrated binding of a
GII.4 virus to saliva from both secretors and non-secretors.
Most surprisingly, we found that saliva from the non-secretor
did not only fail to recognize the Chron GII.3, Norwalk GI.1 but
also the GII.4 Dijon VLP, even though both Valencia/2004/Es
outbreak virus and the Dijon strains belong to GII.4. This
observation implied that the Valencia strain might have HBGA-
receptor specific domains different from the Dijon strain,
suggesting that association of histo-blood group antigens with
susceptibility to NoV infection may be strain-specific rather than
genogroup dependent [38]. Indeed, recent data suggest variations
in HBGA recognition within the GII.4 genotype [33].
To investigate the possibility that the outbreak virus had unique
aa sequence and structural properties in the capsid protein, the P2
domain (aa 248 to 420), of 3 isolates (patients no 207, 208 and 225)
were sequenced and BLAST search was performed. This revealed
that the outbreak strain belonged to the globally dominating GII.4
genotype and was most similar to the Monastir/2003/Tun
[EU916960] strain isolated in Tunisia 2003. The Valencia and
the Monastir capsid were identical in the investigated region
except for a conserved substitution at residue 356, where a valine
in the Monastir strain was changed for an isoleucine in the
Valencia strain. Cao and coworkers [6] have previously proposed
from crystal structure studies that the residues involved in binding
of the A and B trisaccharide to the GII.4 virus (VA387 strain) are
located at the dimer interface and includes residues 343, 344, 345
and 374 from one protomer and 441, 442 and 443 in the other. A
putative carbohydrate-binding patch consisting of residues 329,
373, 375 and 377 located in the P2 domain has also been
suggested by Chakravarty and coworkers [39]. However, since the
sequencing of the Valencia capsid P2 domain did not reveal any
novel mutations in these regions, it is possible that the outbreak
virus may contain other structural determinants that would alter
receptor binding and antigenicity, and thus explaining infection of
the secretor-negative individual and binding to secretor-negative
saliva.
One of the driving forces for NoV evolution, particularly in the
protruding part of the capsid protein, is probably immune evasion
[4,7,33,34,40]. Recent studies have shown that a given NoV
genotype predominates in a season, such as GII.4 in Europe and
the United States [21,41–44]. This predominance of a given
genotype or cluster is followed by a sharp drop in prevalence of the
genotype in the following season [40,44], which again is followed
by the emergence of a genetically distinct lineage. Thus, periods of
phenotypic stasis are followed by the emergence of novel epidemic
strains [33,40].
Allen and co-workers [34] have found two antigenic regions (site
A and B) in the P2 domain of the VA387 crystal structure, where
aa substitutions in this area have impact on the biochemical
properties as well as the entire structure of the P2 domain. These
positions, located to external parts in the capsid, are part of
exposed loops and thus changes in site A and B may have a strong
association with the emergence of novel NoV strains [34]. Since
the non-secretor saliva bound the outbreak strain but not the
Dijon strain, we decided to compare the antigenic site A and B of
the Valencia/2004/Es strain with the Dijon strain. Alignment of
the P2 domain from Valencia/2004/ES and Dijon revealed that
Figure 4. Comparison of antigenic sites between the outbreak Valencia/2004/Es and Dijon strain. The outbreak Valencia/2004/Es strain
have distinct amino acids in antigenic A and B regions of the P2 domain compared to the Dijon strain. Amino acid alignment (Clustal W 1.8 with
default parameters on the European Bioinformatics Institute server) of partial capsid protein (aa 241 to 419) of the Dijon171/96 [AF472623] and the
outbreak Valencia/2004/Es strains. The Valencia/2004/Es sequences, are obtained from three randomly chosen patients (no 207, 208 and 225). The aa
constituting the P2 domain (aa 279 to 405) are shaded in light grey. Antigenic site A (aa 296–298) and site B (393–395) proposed by Allen et al. [34]
are indicated. The Valencia/2004/Es has a TQN and a STT motif in the A and B site, while the Dijon strain have a SHD motif in site A and a –NN motif in
site B. Besides from the A and B site, 11 additional substitutions (marked number 1 to 11) were found when comparing the capsid P2 domain of
Valencia and Dijon, 10 out of these 11 (number 2 to 11) correlated with evolutional hot spots (highlighted by dark grey) identified by Allen and
coworkers [34].
doi:10.1371/journal.pone.0005593.g004
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all three amino acids in both antigenic region A and B were
unique in Valencia/2004/Es as compared to the Dijon strain,
possibly causing the differences in binding properties between the
virus strains.
The Valencia/2004/Es strain have a TQN and a STT motif in
the A and B site respectively, while the Dijon strain have a SHD
motif in site A and a –NN motif in site B. According to Allen and
coworkers, the motif found in the Valencia strain characterize
GII.4 strains isolated in 2004, 2005 and 2006, while the motif from
the Dijon strain are found in strains circulating during 1997, 1998
and 1999 [34]. This pattern correlates well to the year of isolation
both for the Valencia (2004) and the Dijon strains (1996). Besides
from the A and B site, 11 additional substitutions were found when
comparing the capsid P2 domain of Valencia/2004/ES and Dijon
strains, 10 out of these 11 correlated with evolutional hot spots
identified by Allen and coworkers [34]. We therefore speculate
that the aa differences observed in site A, B and in the evolutional
hot spots, may affect the structural and electrostatic properties of
the capsid protein, perhaps giving a clue to the different binding
patterns observed between the Valencia/2004/ES and the Dijon
strain. However, when aligning the Dijon and the Valencia/2004/
ES strains, we also observed differences in aa surrounding the A
and B trisacharide binding site proposed by Cao et al [6]. These
positions include e.g. residue 346, 372, 389 but also residue 393
(part of the antigenic site B identified by Allen and coworkers [34])
which all differ between the Dijon and the Valencia/2004/ES
strains. Of these positions, 393/394 are also identified by
Lindesmith and coworkers, as one site out of six in the NoV
capsid operating under positive selection [33]. Lindesmith and
coworkers suggest that the aa in position 393/394 may play an key
role in receptor binding and impact immunogenic properties of
the virus [33]. Also a study by Siebenga and coworkers describing
epochal evolution of GII.4 capsid proteins, identified position
393/394 as a hypervariable site during evolution [40]. We thereby
can not role out that also the observed differences surrounding the
A and B trisacharide biding site, perhaps in combination with the
changes in antigentic site A and B may contribute to the unusual
saliva binding properties observed in the outbreak virus.
Unfortunately, no host genetic susceptibility data are available
for the Monastir/2003/Tun strain. This would have been most
informative since the capsid protein of the Monastir/2003/Tun
are most similar to the Valencia/2004/ES strain and contain
identical aa in both antigenic site A and B.
Another possibility that might explain the uncommon saliva
binding property observed for the Valencia/2004/Es strain could
be the unexpected appearance of type 1 chain ABH or Lewis b
antigens in patient A and B. To investigate this, Lewis genotyping
and AB(O) and Lewis phenotyping was performed on saliva from
these two patients. These investigations concluded that the patients
are indeed Lea+b2 non-secretors. However, additional structures
used by NoV for binding, may be present in the saliva of these
individuals.
Although sero-epidemiology studies have shown that secretors
have significantly higher antibody titers and prevalence against
NoV than non-secretors [24], the fact that certain non-secretors
are NoV antibody–positive [24,26], suggests that secretor-
independent infections do occur. Also, a few documented NoV
infections of non-secretors have been reported [25,26].
Six of 44 investigated individuals were found to be Lea2b2 by
genotyping. Four of these individuals were secretor-negative and
two were secretor-positive. Of these, only the secretor-positive
Lea2b2 individuals were symptomatically infected. We therefore
speculate that secretor status but not Lewis status may correlate
with NoV susceptibility. Further support for this hypothesis is also
the observation that Lewis status did not predict binding of virus to
saliva (Figure 2). The conclusions are consistent with a previous
observation by Larsson and co-workers [24] who found that
antibody titers and prevalence to NoV correlate with secretor
rather than with Lewis status. This is also in agreement with the
result from Bucardo and co-workers who found NoV susceptibility
to be independent of Lewis-phenotype [45].
While the outbreak-virus infected as well as recognized saliva
from a non-secretor, current information cannot explain why not
all non-secretors were infected or why the virus did not recognize
all non-secretor saliva. Possible explanation for this might be that
the infected secretor-negative individual may express receptors
present in only a limited number of non-secretors, or an unusual
high concentration of a receptor commonly found at low
concentration in non-secretors. Rydell and co-workers recently
showed that GII.3 and GII.4 VLPs could bind Sialyl-Lewis x on
neoglycoproteins, suggesting that this may be a possible determi-
nator of NoV tropism [46]. Also, Taube and co-workers have
suggested a role of sialic acid moieties in murine NoV attachment
to murine macrophages [47]. Furthermore, Tamura and co-
workers have shown that NoV GII VLPs efficiently bind surface
heparin sulfate on the surface of different cell lines [48]. Together
these studies indicate a role of sialylated structures or heparin
sulfate in NoV cell tropism. Another possibility is that certain
individuals are immune. This speculation is supported with data
from other studies showing that not all secretors are infected in a
given outbreak [19]. Furthermore, short term immunity have been
demonstrated in volunteer studies [12].
In conclusion we show for the first time symptomatic NoV
infection caused by a GII.4 strain in a secretor-negative Lea+b2
individual homozygously mutated at nt 428 of FUT2.
Materials and Methods
Subjects and samples
Fecal samples, collected from 26 symptomatic residents and
from 7 staff members, were sent to the local hospital laboratory for
bacteriology and virology investigation. Enteropathogenic bacteria
(Salmonella, Shigella, Campylobacter, Yersinia and Aeromonas species)
were investigated by conventional bacterial culture procedures
[49] and rotavirus and adenovirus were analyzed by enzyme
immunoassay (Premier Rotaclone and Premier Adenoclone 40/
41, Meridian Bioscience Inc., Cincinnati, Oh.) and NoV by RT-
PCR. Saliva samples were collected from 39 residents, including
symptomatic patients and asymptomatic controls and from 21
health care workers of which 11 got sick and 10 remained
asymptomatic (controls).
Characterization of the nonsense FUT2 mutations G428A,
C571T and the missense mutation A385T
The secretor genotype was determined by pyrosequencing as
described [37]. Briefly, DNA was extracted from 200 ml of saliva
using QIAampH DNA Mini kit (Qiagen, Hilden, Germany).
Extracted DNA was stored in TE-buffer in Eppendorf tubes at
220uC until PCR amplification. For PCR amplification forward
primers 59-BIOTIN-GAT GGA GGA GGA ATA CCG CCA C-
39 (FUT2 428), 59CGA CTG GAT GGA GGA GGA ATA C-3
(385) and 59-BIOTIN-GCA CCT TTG TAG GGG TCC A-39
(571) were used together with reverse primers 59-TGG GCC TCC
TCC CGC ACG T-39 (428), 59-CGG TGA AGC GGA CGT
ACT-BIOTIN-39 (385) and 59-CTT CCA CAC TTT TGG CAT
GAC-39 (571). For sequencing the following primers were used: 59-
GGT GGT GGT AGA AGG TC-39 (FUT2 428), 59-GAG GAA
Novel GII.4 Disease Pattern
PLoS ONE | www.plosone.org 7 May 2009 | Volume 4 | Issue 5 | e5593
TAC CGC CAC-39 (385) and 59TGG ACA TAG TCC CCT C-
39 (571).
FUT2 genotyping for mutations G428A, C571T and A385T
was independently also performed by PCR-SSP as published [50].
Determination of Lewis genotype and Lewis and AB
phenotypes of saliva
Lewis genotype was determined using PCR-SSP as described
elsewhere [50], detecting the mutations T59G, T202C, C314T,
G508A and T1067A of the FUT3 gene. Lewis phenotypes were
identified in an ELISA assay [46] using flat-bottom MaxiSorp
Microtiter plates (NUNC, Roskilde, Denmark), anti blood group A
(ABO1 clone 9113D10) and anti B (ABO2 clone 9621A8)
antibodies (Diagast, Loos Cedex, France), anti Lea (Seraclone,
LE1 clone 78FR 2.3) and anti Leb (Seraclone LE2 clones LM129-
181 and 96 FR2.10) antibodies (Biotest AG, Dreieich, Germany)
and finally HRP conjugated goat anti-mouse IgG (170-6516, Bio-
Rad, Hercules, CA, USA.) and TMB (T0440, Sigma) as substrate.
The absorbance values were read at 450 nm (Labsystems iEMS
Reader MF, Labsystems, Helsinki, Finland) and average values for
duplicate wells calculated.
Binding of the outbreak NoV to saliva
To investigate if the outbreak strain could bind to saliva from
symptomatic and asymptomatic individuals, a saliva-based ELISA
was performed as described [19,51] with some modifications.
Saliva samples were boiled, centrifuged at 10,0006g for 5 min,
and diluted 1:500 in coating buffer (0.1 M carbonate-bicarbonate
buffer, pH 9.6). After 2 h of incubation at 37uC followed by
overnight incubation at 4uC, the plates were washed three times
with washing buffer (0.9% NaCl 0.05% Tween 20) and blocked
(3% bovine serum albumin, BSA in PBS) for 60 min at 37uC. A
NoV stool suspension in PBS (10% w/v) was diluted 1:2 in PBS
with 0.05% Tween 20 and 0.5% BSA, and incubated for 2 h at
37uC followed by washing of the plates three times with washing
buffer (0.9% NaCl 0.05% Tween 20) and then incubation with
peroxidase-labeled genogroup I and II-specific NoV polyclonal
antibody (DAKO, Denmark) for 1 h at 37uC. The reaction was
developed using TMB (ICN Biochemicals) and the plate was read
at 450 nm. The cut-off value was three times the mean OD450
value of three known negative control samples.
Binding of NoV VLP to saliva
Norwalk (GI.1) and Dijon (GII.4) purified VLP was a kind gift
from Jacques le Pendu and were used essentially as described above.
Briefly VLP (0.16–2 mg/ml depending on VLP) was diluted in
dilution buffer (0.5% BSA and 0.05% Tween 20 (Sigma) in PBS)
and added to each saliva-coated well, and incubated at 37uC for
1.5 h. Following 36 washes appropriate anti NoV antisera was
incubated for 1.5 h at 37uC. After washing HRP conjugate was
added and incubated for 1.5 hr at 37uC followed by 36washes and
development by TMB as described above. The Chron1 (GII.3) VLP
is a construct from a NoV strain cloned from an patient with a
chronic NoV infection [4]. Production of recombinant VLP was
done in Sf9 cells. Briefly Sf9 cells were infected and harvested 5 days
p.i. Cells and media were then centrifuged at 2000 rpm for 10 min
and the supernatant collected and pelleted by centrifugation at
30 000 rpm, 2 h in SW41Ti and resuspended in PBS followed by
purification in a sucrose gradient. Purity and integrity was
determined by Coomassie staining and western blot [46].
RNA extraction and RT-PCR
Fecal suspensions (10% w/v in PBS) were clarified by low speed
centrifugation. RNA was extracted by using the QIAmp viral
RNA kit, according to the manufacturer’s instructions (QIAGEN,
Hilden, Germany). Purified RNA was then resuspended in 50 ml
of RNase-free water and used as template for RT-PCR using
primer pairs JV12/JV13 [52].
Virus genotyping
Genotyping was performed by nucleotide sequencing of the
PCR products obtained with primers JV12/JV13 (viral RNA
polymerase gene) and Mon381/Mon383 (viral capsid gene) [53].
Sequencing was carried out in both directions using the BigDye
Terminator cycle sequencing kit (Perkin-Elmer) on an automated
ABI PRISM model 377 machine (Applied Biosystems). Sequence
alignments were carried out by using ClustalW1.8 with reference
strains obtained from the Foodborne Virus in Europe (FBVE)
database (https://hypocrates.rivm.nl/bnwww/Divine-Event/in-
dex.html). A dendrogram was constructed using the UPGMA
clustering method with distance calculation using the Jukes-Cantor
correction for evolutionary rate by Molecular Evolutionaty
Genetics Analysis (MEGA version 2.1).
PCR amplification of NoV capsid P2-region
For the reverse transcriptase reaction 5 ml (0.5 mg) pd(N)6
primer (Amersham Biosciences UK Limited, Little Chalfont
Buckinghamshire, UK), 28 ml extracted viral RNA and 17 ml
RNAse free water was added to an Illustra Ready-To-Go RT-
PCR bead (GE-health care, Uppsala, Sweden) and the reaction
was performed at 42uC for 60 minutes followed by inactivation of
the enzymes at 95uC for 5 minutes.
In order to amplify the NoV capsid P2 domain, a PCR reaction
containing 45 ml PCR SuperMix high fidelity (Invitrogen,
Carlsbad, USA), 1 ml 10 mM Val fw1 (59-GAA CTA AAC CAT
TCT CTG TCC C-39) as forward primer, 1 ml 10 mM Val rv1
(59-AAG TGC TGC ACC CA CTC CTG-39) as reverse primer,
and 2 ml cDNA was mixed. The PCR reaction was performed at
94uC for 5 minutes followed by 35 cycles of 94uC for 30 seconds,
53uC for 30 seconds and 68uC for 1 minute, before a final
elongation at 68uC for 10 minutes. PCR-products were visualized
on a 1% agarose gel, using EtBr staining and UV light. The final
PCR amplicon had a length of ,700 bp (nt667 to nt1382).
Sequence analysis
Nucleotide sequencing of the P2 region was performed by
Macrogen Inc. (Seoul, South Korea). The sequencing reaction was
based on BigDye chemistry, using forward primer Val fw1 and
reverse primer Val rv1 as sequencing primers. The amplicons
were sequenced twice in each direction, and complete sequences
were obtained by assembling overlapping contigs with DNASTAR
(DNASTAR, Inc., Madison, Wisconsin, USA). Multiple sequence
alignment of NoV capsid proteins was performed, using the
ClustalW 1.8 algorithm with default parameters on the European
Bioinformatics Institute server. This data was also used for
constructing a phylogenetic tree of the outbreak strain capsid P2
domain and reference strains. The phylogenetic tree was
constructed using the UPGMA clustering method with distance
calculation using the Poisson correction for evolutionary rate by
Molecular Evolutionaty Genetics Analysis (MEGA version 4.1).
Statistical analysis
Fisher’s exact test (two-sided) was used to test significant
differences in distribution of secretor-positive and secretor-
negative individuals among symptomatic and asymptomatic/
non-exposed. Mann-Whitney test was used to compare ELISA
absorbance values between secretor-positive and secretor-negative
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individuals as well as individuals with different Lewis phenotypes
(Lea+b2, Lea2b+ and Lea2b2). SPSS 16 for Mac was used to
perform these analyses and a P-value of ,0.05 was considered
statistically significant.
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